Terms: = Bone cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
281 results:
1. Favorable impact of PD1/pd-l1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation.
Gassner T; Chittilappilly C; Pirich T; Neuditschko B; Hackner K; Lind J; Aksoy O; Graichen U; Klee S; Herzog F; Wiesner C; Errhalt P; Pecherstorfer M; Podar K; Vallet S
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702145
[TBL] [Abstract] [Full Text] [Related]
2. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol.
Banu MA; Raza SM; Amini M; Seaman S; Rubino F; Snyder R; Patel S; DeMonte F; Conley AP
Neurosurg Focus; 2024 May; 56(5):E15. PubMed ID: 38691867
[TBL] [Abstract] [Full Text] [Related]
3. New advances in the treatment of chondrosarcoma under the PD-1/pd-l1 pathway.
Yin J; Ren P
J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract] [Full Text] [Related]
5. Visual analysis of bone malignancies immunotherapy: A bibliometric analysis from 2010 to 2023.
Shen K; Yang L; Ke S; Gao W
Medicine (Baltimore); 2024 Mar; 103(13):e37269. PubMed ID: 38552042
[TBL] [Abstract] [Full Text] [Related]
6. Utility of molecular markers in predicting local control specific to lung cancer spine metastases treated with stereotactic body radiotherapy.
Shor D; Louie AV; Zeng KL; Menjak IB; Atenafu EG; Chia-Lin Tseng ; Detsky J; Larouche J; Zhang B; Soliman H; Myrehaug S; Maralani P; Hwang DM; Sahgal A; Chen H
J Neurooncol; 2024 Apr; 167(2):275-283. PubMed ID: 38526757
[TBL] [Abstract] [Full Text] [Related]
7. [Efficacy of combined treatment with pirfenidone and pd-l1 inhibitor in mice bearing ectopic bladder cancer xenograft].
Chen S; Zhang S; Fan W; Sun W; Liu B; Liu J; Guo Y
Nan Fang Yi Ke Da Xue Xue Bao; 2024 Feb; 44(2):210-216. PubMed ID: 38501405
[TBL] [Abstract] [Full Text] [Related]
8. Large-scale bioreactor production of extracellular vesicles from mesenchymal stromal cells for treatment of acute radiation syndrome.
Kink JA; Bellio MA; Forsberg MH; Lobo A; Thickens AS; Lewis BM; Ong IM; Khan A; Capitini CM; Hematti P
Stem Cell Res Ther; 2024 Mar; 15(1):72. PubMed ID: 38475968
[TBL] [Abstract] [Full Text] [Related]
9. [Adenocarcinoma with Aplastic Anemia as an Immune-related Adverse Event Caused by Pembrolizumab: Report of a Case].
Hashimoto S; Haga N; Morimoto M; Doi Y
Kyobu Geka; 2024 Mar; 77(3):235-238. PubMed ID: 38465499
[TBL] [Abstract] [Full Text] [Related]
10. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for Osteosarcoma treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract] [Full Text] [Related]
11. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review).
Hiraga T
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38362963
[TBL] [Abstract] [Full Text] [Related]
12. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract] [Full Text] [Related]
13. First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti pd-l1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET.
Pouw JEE; Hashemi SMS; Huisman MC; Wijngaarden JE; Slebe M; Oprea-Lager DE; Zwezerijnen GJC; Vugts D; Ulas EB; de Gruijl TD; Radonic T; Senan S; Menke-van der Houven van Oordt CW; Bahce I
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302416
[TBL] [Abstract] [Full Text] [Related]
14. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
15. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
[TBL] [Abstract] [Full Text] [Related]
16. A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma.
Li L; Chen L; Fan M; Tian Y; Ai H; Yan L; Li F; Lan M; Lai X; Huang Y; Xu P; Feng M; Lang J
Oral Oncol; 2024 Mar; 150():106695. PubMed ID: 38262250
[TBL] [Abstract] [Full Text] [Related]
17. Imaging diagnosis and efficacy monitoring by [
He H; Qi X; Fu H; Xu J; Zheng Q; Chen L; Zhang Y; Hua H; Xu W; Xu Z; Chen X; You Q; Lin J; Huang G; Mao Y; Yu C
Theranostics; 2024; 14(1):392-405. PubMed ID: 38164149
[No Abstract] [Full Text] [Related]
18. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
LaMarche NM; Hegde S; Park MD; Maier BB; Troncoso L; Le Berichel J; Hamon P; Belabed M; Mattiuz R; Hennequin C; Chin T; Reid AM; Reyes-Torres I; Nemeth E; Zhang R; Olson OC; Doroshow DB; Rohs NC; Gomez JE; Veluswamy R; Hall N; Venturini N; Ginhoux F; Liu Z; Buckup M; Figueiredo I; Roudko V; Miyake K; Karasuyama H; Gonzalez-Kozlova E; Gnjatic S; Passegué E; Kim-Schulze S; Brown BD; Hirsch FR; Kim BS; Marron TU; Merad M
Nature; 2024 Jan; 625(7993):166-174. PubMed ID: 38057662
[TBL] [Abstract] [Full Text] [Related]
19. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
[TBL] [Abstract] [Full Text] [Related]
20. A tumor-associated heparan sulfate-related glycosaminoglycan promotes the generation of functional regulatory T cells.
Martín-Cruz L; Viñuela M; Kalograiaki I; Angelina A; Oquist-Phillips P; Real-Arévalo I; Cañada FJ; Tudela JI; Moltó L; Moreno-Sierra J; Subiza JL; Palomares O
Cell Mol Immunol; 2023 Dec; 20(12):1499-1512. PubMed ID: 37990034
[TBL] [Abstract] [Full Text] [Related]
[Next]